SEC Form 4 · accession 0000950103-16-014335

Anacor Pharmaceuticals, Inc. · ANAC

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP and Chief Medical Officer

Period of report

Jun 24, 2016

Accepted (ET)

Jun 24, 2016 · 2:49 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001411158

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Jun 24, 2016	D	44,194	$99.25	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Performance Restricted Stock Units^F1	—	Jun 24, 2016	D	6,350	D	—	—	Common Stock	6,350	D
Performance Restricted Stock Units^F1	—	Jun 24, 2016	D	4,375	D	—	—	Common Stock	4,375	D
Stock Option (right to buy)^F1	$5.00	Jun 24, 2016	D	3,849	D	—	—	Common Stock	3,849	D
Stock Option (right to buy)^F1	$5.59	Jun 24, 2016	D	27,661	D	—	—	Common Stock	27,661	D
Stock Option (right to buy)^F1	$6.92	Jun 24, 2016	D	33,239	D	—	—	Common Stock	33,239	D
Stock Option (right to buy)^F1	$6.96	Jun 24, 2016	D	80,000	D	—	—	Common Stock	80,000	D
Stock Option (right to buy)^F1	$7.25	Jun 24, 2016	D	12,957	D	—	—	Common Stock	12,957	D
Stock Option (right to buy)^F1	$12.49	Jun 24, 2016	D	30,000	D	—	—	Common Stock	30,000	D
Stock Option (right to buy)^F1	$17.14	Jun 24, 2016	D	47,000	D	—	—	Common Stock	47,000	D
Stock Option (right to buy)^F1	$37.81	Jun 24, 2016	D	24,360	D	—	—	Common Stock	24,360	D
Stock Option (right to buy)^F1	$78.91	Jun 24, 2016	D	22,136	D	—	—	Common Stock	22,136	D

F1As of the effective time of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 14, 2016 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Quattro Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent, pursuant to the terms of the Merger Agreement, (i) each share of the Issuer's Common Stock held by the reporting person was disposed of in exchange for the merger consideration of $99.25 per share, (ii) each award of restricted stock units (including performance restricted stock units) and stock options became fully vested and (iii) each award of restricted stock units (including performance restricted stock units) and stock options was cancelled in exchange for the right to receive a cash payment per share in an amount equal to $99.25 less, in the case of stock options, the applicable exercise price.
F2Includes shares acquired pursuant to the Issuer's ESPP since the reporting person's last Form 4.